$526 Million is the total value of BVF INC/IL's 31 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 46.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IRWD | Sell | IRONWOOD PHARMACEUTICALS INC | $78,037,000 | +7.6% | 5,093,810 | -9.0% | 15.18% | +0.8% |
| CCXI | CHEMOCENTRYX INC | $58,716,000 | +51.8% | 8,596,772 | 0.0% | 11.42% | +42.2% | |
| ARRY | Sell | ARRAY BIOPHARMA INC | $55,683,000 | +12.4% | 11,772,335 | -15.2% | 10.83% | +5.3% |
| LGND | Sell | LIGAND PHARMACEUTICALS INC | $45,764,000 | -12.2% | 860,063 | -22.4% | 8.90% | -17.7% |
| OMED | Buy | ONCOMED PHARMACEUTICALS INC | $29,916,000 | +22.7% | 1,374,815 | +6.8% | 5.82% | +15.0% |
| ONTY | Buy | ONCOTHYREON INC | $26,148,000 | +38.0% | 13,762,260 | +39.5% | 5.09% | +29.3% |
| FPRX | Sell | FIVE PRIME THERAPEUTICS INC | $22,311,000 | +30.1% | 826,332 | -43.5% | 4.34% | +21.9% |
| FWP | New | FORWARD PHARMA A/Ssponsored adr | $21,921,000 | – | 1,052,381 | +100.0% | 4.26% | – |
| CYTK | Buy | CYTOKINETICS INC | $19,569,000 | +264.1% | 2,443,100 | +60.0% | 3.81% | +241.1% |
| Buy | EXELIXIS INCnote 4.250% 8/1 | $18,093,000 | +80.7% | 31,239,000 | +81.9% | 3.52% | +69.3% | |
| TRGT | TARGACEPT INC | $17,503,000 | +4.0% | 6,655,128 | 0.0% | 3.40% | -2.6% | |
| CNCE | CONCERT PHARMACEUTICALS INC | $16,070,000 | +5.6% | 1,206,459 | 0.0% | 3.13% | -1.0% | |
| LOXO | Sell | LOXO ONCOLOGY INC | $13,991,000 | -10.6% | 1,190,702 | -0.1% | 2.72% | -16.2% |
| VTAE | Buy | VITAE PHARMACEUTICALS INC | $12,545,000 | +146.9% | 753,935 | +13.2% | 2.44% | +131.3% |
| XENE | New | XENON PHARMACEUTICALS INC | $12,210,000 | – | 618,224 | +100.0% | 2.38% | – |
| QLTI | Buy | QLT INC | $10,629,000 | +12.3% | 2,650,563 | +26.6% | 2.07% | +5.2% |
| Sell | ARRAY BIOPHARMA INCnote 3.000% 06/0 | $8,477,000 | -41.1% | 9,000,000 | -43.8% | 1.65% | -44.8% | |
| GTXI | New | GTX INC DEL | $8,111,000 | – | 11,111,111 | +100.0% | 1.58% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $7,997,000 | – | 3,136,000 | +100.0% | 1.56% | – |
| EXEL | New | EXELIXIS INC | $6,041,000 | – | 4,195,352 | +100.0% | 1.18% | – |
| ARQL | Buy | ARQULE INC | $5,763,000 | +19.6% | 4,723,811 | +9.8% | 1.12% | +12.1% |
| MSTX | New | MAST THERAPEUTICS INC | $4,083,000 | – | 7,291,600 | +100.0% | 0.79% | – |
| OGXI | Buy | ONCOGENEX PHARMACEUTICALS IN | $3,134,000 | +77.3% | 1,368,500 | +106.7% | 0.61% | +66.2% |
| BLRX | BIOLINERX LTDsponsored adr | $2,432,000 | +5.2% | 1,501,000 | 0.0% | 0.47% | -1.5% | |
| KBIO | KALOBIOS PHARMACEUTICALS INC | $2,010,000 | +11.6% | 1,162,000 | 0.0% | 0.39% | +4.5% | |
| AKAOQ | ACHAOGEN INC | $1,783,000 | +45.7% | 136,600 | 0.0% | 0.35% | +36.6% | |
| RGDO | Sell | REGADO BIOSCIENCES INC | $1,719,000 | -41.6% | 1,882,521 | -27.8% | 0.33% | -45.4% |
| New | APTOSE BIOSCIENCES INC | $986,000 | – | 166,664 | +100.0% | 0.19% | – | |
| BOTA | BIOTA PHARMACEUTIALS INC | $976,000 | -9.4% | 435,900 | 0.0% | 0.19% | -15.2% | |
| ANTH | ANTHERA PHARMACEUTICALS INC | $884,000 | -17.7% | 559,624 | 0.0% | 0.17% | -22.9% | |
| SPHS | Buy | SOPHIRIS BIO INC | $573,000 | -67.4% | 1,060,283 | +76.7% | 0.11% | -69.6% |
| TSPT | Exit | TRANSCEPT PHARMACEUTICALS IN | $0 | – | -150,000 | -100.0% | -0.06% | – |
| PTN | Exit | PALATIN TECHNOLOGIES INC | $0 | – | -750,655 | -100.0% | -0.14% | – |
| QURE | Exit | UNIQURE NV | $0 | – | -106,500 | -100.0% | -0.20% | – |
| RGLS | Exit | REGULUS THERAPEUTICS INC | $0 | – | -184,999 | -100.0% | -0.26% | – |
| ARDX | Exit | ARDELYX INC | $0 | – | -453,541 | -100.0% | -1.34% | – |
| TRVN | Exit | TREVENA INC | $0 | – | -1,118,743 | -100.0% | -1.49% | – |
| PRQR | Exit | PROQR THRAPEUTICS N V | $0 | – | -549,000 | -100.0% | -1.96% | – |
| RCPT | Exit | RECEPTOS INC | $0 | – | -1,146,300 | -100.0% | -14.78% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.